Both in Pharmaceuticals
Design Therapeutics vs Geron
Over the past year DSGN returned +66.9% and GERN returned −10.2%; their daily moves had a correlation of 0.27.
DSGN +66.9% GERN −10.2%Growth of $1, one year, split-adjusted
| Metric | DSGN | GERN |
|---|---|---|
| Price | $12.57 | $1.23 |
| Market cap | $786.7M | $790.2M |
| Today | −0.40% | −0.81% |
| 1 month | −16.7% | −17.4% |
| 6 months | +18.1% | −17.4% |
| Year to date | +34.0% | −6.8% |
| 1 year | +83.5% | −6.1% |
| Revenue growth (YoY) | — | +17.2% |
| Gross margin | — | 83.9% |
| Net margin | — | −29.0% |
| P/E (TTM) | — | — |
| Price / sales | — | 3.9× |
| Net cash | $207.4M | $51.1M |
| Dividend yield | — | — |
| Volatility (60d) | 52.5% | 66.0% |
| Short % of float | 21.1% | 13.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).